AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33568163 — intervention group
Group type: COMPARATOR
Intervention: Control group (before running mode)
Number of subjects: 1562
Study 33783109 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective metastasectomy
Number of subjects: 481
Study 33783109 — intervention group
Group type: COMPARATOR
Intervention: No metastasectomy
Number of subjects: 481
Study 36205036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Sitting (3-min of moderate-intensity walking every 30 min for 3 h daily)
Number of subjects: 109
Study 36205036 — intervention group
Group type: COMPARATOR
Intervention: Control (3 h of daily Uninterrupted Sitting)
Number of subjects: 109
Study 32618875 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS screening trial strategy (TG)
Number of subjects: 105
Study 32618875 — intervention group
Group type: COMPARATOR
Intervention: No trial screening strategy (NTG)
Number of subjects: 105
Study 32618875 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS screening trial (TG)
Number of subjects: 105
Study 32618875 — intervention group
Group type: COMPARATOR
Intervention: SCS screening trial (TG) vs No trial screening (NTG)
Number of subjects: 105
Study 34036692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed-platinum
Number of subjects: 40
Study 34036692 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed-platinum
Number of subjects: 40
Study 32909468 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 0
Study 32909468 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control group
Number of subjects: 0
Study 36137628 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based care support (SBCS) programme
Number of subjects: 180
Study 36137628 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study 36193755 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based model using clinical data
Number of subjects: 1356
Study 36193755 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based model using chest radiographs
Number of subjects: 1356
Study 36193755 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based model using both clinical data and chest radiographs (mixed model)
Number of subjects: 1356
Study 32037269 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 223
Study 32037269 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 223
Study 32037269 — intervention group
Group type: COMPARATOR
Intervention: Aspirin/Dipyridamole
Number of subjects: 223
Study 35508113 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG signals during balance perturbation task
Number of subjects: 7
Study 35508113 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network trained on single-trial EEG
Number of subjects: 7
Study 35508113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic functional connectivity analysis
Number of subjects: 7
Study 35508113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-time decoding of COP trajectories from EEG using a gated recurrent unit model
Number of subjects: 7
Study 33650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction with a therapy dog (no physical interaction)
Number of subjects: 75
Study 33650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Social plus physical interaction with a therapy dog
Number of subjects: 75
Study 33650444 — intervention group
Group type: COMPARATOR
Intervention: No interaction with a therapy dog (control)
Number of subjects: 75
Study 32463593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate ODT (50 mg) without water
Number of subjects: 36
Study 32463593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate ODT (50 mg) with water
Number of subjects: 36
Study 32463593 — intervention group
Group type: COMPARATOR
Intervention: Conventional sildenafil citrate tablets (50 mg) with water
Number of subjects: 36
Study 35395638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Number of subjects: 27
Study 35395638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33373763 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy to achieve a target INR of 1.5–2
Number of subjects: 86
Study 33373763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 86
Study 32755488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone included with multimodal pain medications (group 1)
Number of subjects: 95
Study 32755488 — intervention group
Group type: COMPARATOR
Intervention: Optional prescription for oxycodone (group 2)
Number of subjects: 95
Study 32755488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 95
Study 34762211 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 25
Study 34762211 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 25
Study 34488843 — intervention group
Group type: COMPARATOR
Intervention: Status quo framing (1500 respondents)
Number of subjects: 12000
Study 34488843 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative risk labels (e.g. 'very low risk')
Number of subjects: 12000
Study 34488843 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to COVID-19 mortality
Number of subjects: 12000
Study 34488843 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to motor vehicle mortality
Number of subjects: 12000
Study 34488843 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute vs relative risk presentation
Number of subjects: 12000
Study 33788454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (20 minutes each session, once every other day for 8 weeks)
Number of subjects: 210
Study 33788454 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Nimodipine 30 mg once a day for 8 weeks)
Number of subjects: 210
Study 33788454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 210
Study 35970829 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 130
Study 35970829 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 130
Study 35970829 — intervention group
Group type: COMPARATOR
Intervention: Combination of exercise and liraglutide
Number of subjects: 130
Study 35970829 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 130
Study 34491645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (at Neiguan (PC 6), Hegu (LI 4), Yintang (GV 29), and Baihui (GV 20), twice a day until mechanical ventilation was offline)
Number of subjects: 188
Study 34491645 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing and treatment of severe pneumonia (Control group)
Number of subjects: 188
Study 32353805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 92
Study 32353805 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (50 μg/kg) with 8 μg/kg glycopyrrolate
Number of subjects: 92
Study 32353805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 92
Study 32353805 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 92
Study 36274079 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared emitting fabric (FIR)
Number of subjects: 10
Study 36274079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2)
Number of subjects: 200
Study 32910179 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 32910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 200
Study 32027446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) with 240 mL of 0% alcohol
Number of subjects: 20
Study 32027446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) with 240 mL of 40% alcohol
Number of subjects: 20
Study 32027446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone twice-daily (OTD) with 240 mL of 40% alcohol
Number of subjects: 20
Study 32027446 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone twice-daily (OTD) with 240 mL of 0% alcohol
Number of subjects: 20
Study 35923485 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos of 'people like me' (patient stories)
Number of subjects: 14
Study 34177615 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser PBM (100 mW output power, irradiance of 35.7 W cm–2, total energy of 28 J/arm)
Number of subjects: 13
Study 34177615 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser PBM
Number of subjects: 13
Study 34177615 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser PBM and Placebo
Number of subjects: 13
Study 35121204 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 35121204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33829742 — intervention group
Group type: COMPARATOR
Intervention: 3-minute balloon inflation
Number of subjects: 61
Study 33829742 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute balloon inflation
Number of subjects: 61
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses consulting patients and providing follow-up care in diabetes management in 2016
Number of subjects: 26
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses completing Diabetes Annual Reviews independently of doctors in 2016
Number of subjects: 26
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to educational resources by nurses in 2016
Number of subjects: 26
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Support felt by nurses for participating in diabetes reviews in 2016
Number of subjects: 26
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses addressing cardiovascular risk factors during reviews in 2016
Number of subjects: 26
Study 35065898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses reporting participation in diabetes reviews conducted by designated nurses in 2016
Number of subjects: 26
Study 33517855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertensive and hypertensive group
Number of subjects: 171
Study 33517855 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese BMI group
Number of subjects: 171
Study 33517855 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 171
Study 33517855 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 171
Study 33517855 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and BP
Number of subjects: 171
Study 36691187 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain communication about COVID-19 vaccine effectiveness
Number of subjects: 328
Study 36691187 — intervention group
Group type: COMPARATOR
Intervention: Uncertain communication about COVID-19 vaccine effectiveness
Number of subjects: 328
Study 32202658 — intervention group
Group type: EXPERIMENTAL
Intervention: QEWP-C-5
Number of subjects: 218
Study 32202658 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC-ED-Q
Number of subjects: 218
Study 32202658 — intervention group
Group type: COMPARATOR
Intervention: EDE
Number of subjects: 218
Study 32202658 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC-eating presence
Number of subjects: 218
Study 34519709 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle flap reconstruction
Number of subjects: 145
Study 33179380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall obesity (measured by Body Mass Index - BMI)
Number of subjects: 74317
Study 33179380 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (measured by Waist Circumference - WC)
Number of subjects: 74317
Study 33179380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall obesity (BMI)
Number of subjects: 74317
Study 33179380 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC)
Number of subjects: 74317
Study 36411989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein diet (LC/HP, 30% energy from protein, 40% energy from carbohydrate)
Number of subjects: 25
Study 36411989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein diet (LC/HP)
Number of subjects: 25
Study 36411989 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 25
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: COMPARATOR
Intervention: trazodone-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: desvenlafaxine-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline-placebo
Number of subjects: 258
Study 32894088 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine-placebo
Number of subjects: 258
Study 36261056 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training of the nonhemiplegic side (NHS)
Number of subjects: 139
Study 36261056 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation training (control group)
Number of subjects: 139
Study 33640289 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL mentholated popsicle
Number of subjects: 50
Study 33640289 — intervention group
Group type: COMPARATOR
Intervention: Usual care (absolute fasting)
Number of subjects: 50
Study 32998416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Number of subjects: 88
Study 32998416 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Dietary Prescription
Number of subjects: 88
Study 36327327 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provision messages about recycling
Number of subjects: 0
Study 36327327 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32160096 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 145
Study 32160096 — intervention group
Group type: COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 145
Study 34214153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 or 30 μg daily)
Number of subjects: 525
Study 32434376 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapy (Group A)
Number of subjects: 50
Study 32434376 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Group B)
Number of subjects: 50
Study 36169160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/daily
Number of subjects: 40
Study 36169160 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol lotion 0.05% once at night
Number of subjects: 40
Study 33370050 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen (NSAID)
Number of subjects: 70
Study 33370050 — intervention group
Group type: COMPARATOR
Intervention: 5 mg hydrocodone with 325 mg acetaminophen (opioid)
Number of subjects: 70
Study 33941951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 164
Study 33941951 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 164
Study 32059704 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Gemcitabine + Cisplatin (3 cycles pre- and post-surgery)
Number of subjects: 333
Study 32059704 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone followed by therapy of investigator's choice
Number of subjects: 333
Study 34739947 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 151
Study 35056349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electroacupuncture at left PC5, PC6, ST36, and ST37, once weekly for 12 weeks)
Number of subjects: 44
Study 35056349 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment (control group)
Number of subjects: 44
Study 35056349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 44
Study 35056349 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 44
Study 35413570 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (30 mg/day)
Number of subjects: 50
Study 35413570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33036591 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAPE group intervention (10-week course delivered as group sessions)
Number of subjects: 372
Study 33036591 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 372
Study 36498457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (5 μg; n = 35)
Number of subjects: 70
Study 36498457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 70
Study 32008289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 100
Study 32008289 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (2 mg) combined with atropine (0.5-1.0 mg)
Number of subjects: 100
Study 35268040 — intervention group
Group type: EXPERIMENTAL
Intervention: IGOBE program (healthy lifestyle habits program in six weekly sessions)
Number of subjects: 456
Study 35268040 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 456
Study 35268040 — intervention group
Group type: EXPERIMENTAL
Intervention: IGOBE program
Number of subjects: 456
Study 34860129 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory exergame training (IG: n=29)
Number of subjects: 50
Study 34860129 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n=21)
Number of subjects: 50
Study 37415125 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Decision Tree (GBDT)
Number of subjects: 231
Study 37415125 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 231
Study 37415125 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree (DT)
Number of subjects: 231
Study 37415125 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning Classifiers (GBDT and LR)
Number of subjects: 231
Study 37415125 — intervention group
Group type: EXPERIMENTAL
Intervention: Long diameter (CT feature)
Number of subjects: 231
Study 32930011 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Family Intervention (CulFI)
Number of subjects: 0
Study 32930011 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 0
Study 36167891 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dispersible zinc tablets (TZ)
Number of subjects: 200
Study 36167891 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient powder (MNP)
Number of subjects: 200
Study 36167891 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily preventive zinc tablets (PZ)
Number of subjects: 200
Study 36167891 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder (control)
Number of subjects: 200
Study 34101714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 μg kg‐1 h‐1) combined with GDHT
Number of subjects: 160
Study 34101714 — intervention group
Group type: COMPARATOR
Intervention: Saline combined with GDHT
Number of subjects: 160
Study 34101714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 160
Study 34101714 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study 33290900 — intervention group
Group type: EXPERIMENTAL
Intervention: High clonogenic potential (CP) STBSs cultures
Number of subjects: 54
Study 33290900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low clonogenic potential (CP) STBSs cultures
Number of subjects: 54
Study 32340838 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy and Dry Needling (ESWT-DN)
Number of subjects: 40
Study 32340838 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 40
Study 34510243 — intervention group
Group type: EXPERIMENTAL
Intervention: CSC‐C (Continuous Single Culture Complete)
Number of subjects: 226
Study 34510243 — intervention group
Group type: COMPARATOR
Intervention: G5 series (Vitrolife)
Number of subjects: 226
Study 34510243 — intervention group
Group type: EXPERIMENTAL
Intervention: CSC‐C
Number of subjects: 226
Study 34510243 — intervention group
Group type: COMPARATOR
Intervention: G5 series
Number of subjects: 226
Study 33309486 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based surveillance after immunisation
Number of subjects: 6555
Study 35648095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting (phlebotomy)
Number of subjects: 14
Study 35648095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy procedures
Number of subjects: 14
Study 34318597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (1 mg)
Number of subjects: 0
Study 34318597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (3 mg)
Number of subjects: 0
Study 34318597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (10 mg)
Number of subjects: 0
Study 34318597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (1, 3, or 10 mg)
Number of subjects: 0
Study 34318597 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0